The BioCollective® Awarded Groundbreaking Probiotic Patent
Retrieved on:
Thursday, March 7, 2024
Ecology, The, Diabetes, Parkinson's disease, Probiotic, Human microbiome, Carbohydrate metabolism, Pediococcus acidilactici, Blood, Patent, Use, Disease, Health, Type 2 diabetes, Triglyceride, Leuconostoc mesenteroides, DSM-IV codes, Patient, Insulin, United States patent law, Clinical trial, Research, Dietary supplement
DENVER, March 7, 2024 /PRNewswire-PRWeb/ -- The BioCollective, a pioneer in microbiome research and consumer probiotics, today announced it has been granted a patent for a system of probiotics to manage and potentially treat a range of significant health issues.
Key Points:
- The issued composition-of-matter patent covers probiotic formulations to prevent or limit disease conditions, restore lost physiological function, and reduce gastrointestinal infection by modulating gastrointestinal mannitol.
- The patent covers a range of clinical conditions, including diabetes, metabolic diseases, gastrointestinal infections, and neurological diseases.
- The US Patent and Trademark Office issued US Patent No.
- The company's BiotiQuest® Sugar Shift® probiotic and additional products in its development pipeline are covered under the patent.